V. Balasubramanian

Trying 3106016892...Open

Welcome to STN International! Enter x:x
LOGINID:ssspta1611bxv
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Aug 21	Instant Access to FDA Regulatory Information with DIOGENES
NEWS	3	Aug 21	CAS patent coverage expanded
NEWS	4	Aug 24	TABULATE Now Available in More STN Databases
NEWS	5	Aug 28	MEDLINE from 1958 to Date - Only on STN
NEWS	6	Sep 7	DGENE GETSIM ALERT: Similarity Current-Awareness Searching of Biosequences
NEWS	7	Sep 11	Textile Technology Digest (TEXTILETECH) now available on STN
NEWS	8	Sep 21	KKF renamed DKILIT
NEWS	9	Sep 29	The Philippines Inventory of Chemicals and Chemical Substances (PICCS) has been added to CHEMLIST

NEWS EXPRESS	FREE UPGRADE 5.0D FOR STN EXPRESS 5.0 WITH DISCOVER! (WINDOWS) NOW AVAILABLE
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:32:00 ON 05 OCT 2000

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

FILE 'REGISTRY' ENTERED AT 15:32:06 ON 05 OCT 2000
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 4 OCT 2000 HIGHEST RN 292819-21-7
DICTIONARY FILE UPDATES: 4 OCT 2000 HIGHEST RN 292819-21-7

V. Balasubramanian

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 11, 2000

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT
for details.

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=>
Uploading c:\stnexp4\queries\09543703.str

L1 STRUCTURE UPLOADED

=> que L1

L2 QUE L1

=> d l1

L1 HAS NO ANSWERS
L1 STR



G1 C,H,O,N

G2 N,OH

G3 H,Me,Ak

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 15:32:42 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 11130 TO ITERATE

9.0% PROCESSED 1000 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

V. Balasubramanian

PROJECTED ITERATIONS: 216297 TO 228903
PROJECTED ANSWERS: 42770 TO 48496

L3 50 SEA SSS SAM L1

=> d scan 1-50

'1-50' IS NOT A VALID FORMAT FOR FILE 'REGISTRY'

L3 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Cytidine, 5'-O-[bis(4-methoxyphenyl)phenylmethyl]-2'-deoxy-N-[[4-(1,1-dimethylethyl)phenoxy]acetyl]-, 3'-[ethyl bis(1-methylethyl)phosphoramidite] (9CI)
MF C50 H63 N4 O9 P

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B

OMe

The following are valid formats:

Substance information can be displayed by requesting individual fields or predefined formats. The predefined substance formats are: (RN = CAS Registry Number)

REG - RN
SAM - Index Name, MF, and structure - no RN
FIDE - All substance data, except sequence data
IDE - FIDE, but only 50 names
SQIDE - IDE, plus sequence data
SQIDE3 - Same as SQIDE, but 3-letter amino acid codes are used
SQD - Protein sequence data, includes RN
SQD3 - Same as SQD, but 3-letter amino acid codes are used
SQN - Protein sequence name information, includes RN

Any CA File format may be combined with any substance format to obtain CA references citing the substance. The substance formats must be cited first. The CA File predefined formats are:

ABS -- Abstract
APPS -- Application and Priority Information
BIB -- CA Accession Number, plus Bibliographic Data
CAN -- CA Accession Number
CBIB -- CA Accession Number, plus Bibliographic Data (compressed)
IND -- Index Data
IPC -- International Patent Classification
PATS -- PI, SO
STD -- BIB, IPC, and NCL

IABS --ABS, indented, with text labels
IBIB -- BIB, indented, with text labels
ISTD -- STD format, indented

OBIB -------- AN, plus Bibliographic Data (original)
OIBIB ------- OBIB, indented with text labels

SBIB -------- BIB, no citations
SIBIB ------- IBIB, no citations

The ALL format gives FIDE BIB ABS IND RE, plus sequence data when it is available.
The MAX format is the same as ALL.
The IALL format is the same as ALL with BIB ABS and IND indented, with text labels.

For additional information, please consult the following help messages:

HELP DFIELDS -- To see a complete list of individual display fields.
HELP FORMATS -- To see detailed descriptions of the predefined formats.
HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10

L3 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN L-glycero-D-galacto-Nonitol, 2,6-anhydro-9-O-[3-(carboxymethoxy)-5-(methoxycarbonyl)phenyl]-1,7,8-trideoxy-3,4,5-tris-O-(phenylmethyl)- (9CI)
MF C40 H44 O10

V. Balasubramanian

Absolute stereochemistry.



L3 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Butanamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[4-[[(hydroxyamino)carbonyl]amino]-3,5-dimethylphenyl]- (9CI)
MF C29 H43 N3 O4



L3 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Benzoic acid, 4-chloro-3-[[2-[4-[[[[[4-[2-cyano-2-[5-(1,1-dimethylethyl)-2-benzoxazolyl]ethenyl]-3-methylphenyl]cyclopentylamino]carbonyl]oxy]methyl]-2-[(methylsulfonyl)amino]phenoxy]-3-(1-methylcyclopropyl)-1,3-dioxopropyl]amino]-, dodecyl ester (9CI)
MF C61 H74 Cl N5 O10 S

PAGE 1-A



PAGE 1-B



L3 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Butanamide, 2-[2,4-bis(1,1-dimethylpropyl)phenoxy]-N-[2-[[3-[[2-chloro-5-(3-hexadecyl-2,5-dioxo-1-pyrrolidinyl)phenyl]amino]-4,5-dihydro-5-oxo-1-(2,4,6-trichlorophenyl)-1H-pyrazol-4-yl]thio]phenyl]- (9CI)
MF C61 H79 Cl4 N5 O5 S



L3 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Benzenepropanoic acid, .beta.-[[[4-[(1E)-2-(4-chlorophenyl)ethenyl]phenoxy]acetyl]amino]-, (2E)-[(3-hydroxyphenyl)methylene]hydrazide (9CI)
MF C32 H28 Cl N3 O4

Double bond geometry as shown.

PAGE 1-A



PAGE 1-B



L3 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN .beta.-Alanine, N-[1-oxo-4-(4-piperidinyl)-2-[2-(4-piperidinyl)ethyl]butyl]glycyl-3-[3-(carboxymethoxy)phenyl]-, dihydrochloride (9CI)
MF C29 H44 N4 O7 . 2 Cl H



●2 HCl

L3 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Acetic acid, [4-[[2-butyl-5-[(4-hydroxybenzoyl)amino]-3-benzofuranyl]carbonyl]-2,6-diiodophenoxy]- (9CI)
MF C28 H23 I2 N O7



L3 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Acetamide, 2-phenoxy-N-(3,3,3-trifluoro-2-hydroxy-1-methylpropyl)-, [S-(R*,R*)]- (9CI)
MF C12 H14 F3 N O3

Absolute stereochemistry.



L3 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Acetic acid, [2-[(1R,2S,3R)-2-(aminomethyl)-3-(1,3-benzodioxol-5-yl)-2,3-

dihydro-6-propoxy-1H-inden-1-yl]-5-methoxyphenoxy]-, rel- (9CI)
MF C29 H31 N O7

Relative stereochemistry.



L3 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Acetic acid, [3-[(1Z)-3-[[[phenyl(phenylmethyl)amino]carbonyl]oxy]-1-propenyl]phenoxy]-, compd. with 2-methyl-2-propanamine (1:1) (9CI)
MF C25 H23 N O5 . C4 H11 N

CM 1

Double bond geometry as shown.



CM 2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> log y

V. Balasubramanian

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.90	1.05

STN INTERNATIONAL LOGOFF AT 15:33:56 ON 05 OCT 2000

Trying 3106016892...Open

Welcome to STN International! Enter x:x
LOGINID:ssspta1611bxv
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2	Aug 21	Instant Access to FDA Regulatory Information with DIOGENES
NEWS	3	Aug 21	CAS patent coverage expanded
NEWS	4	Aug 24	TABULATE Now Available in More STN Databases
NEWS	5	Aug 28	MEDLINE from 1958 to Date - Only on STN
NEWS	6	Sep 7	DGENE GETSIM ALERT: Similarity Current-Awareness Searching of Biosequences
NEWS	7	Sep 11	Textile Technology Digest (TEXTILETECH) now available on STN
NEWS	8	Sep 21	KKF renamed DKILIT
NEWS	9	Sep 29	The Philippines Inventory of Chemicals and Chemical Substances (PICCS) has been added to CHEMLIST

NEWS EXPRESS	FREE UPGRADE 5.0D FOR STN EXPRESS 5.0 WITH DISCOVER! (WINDOWS) NOW AVAILABLE
NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:36:51 ON 05 OCT 2000

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.15	0.15

V. Balasubramanian

FILE 'REGISTRY' ENTERED AT 15:36:55 ON 05 OCT 2000
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

STRUCTURE FILE UPDATES: 4 OCT 2000 HIGHEST RN 292819-21-7
DICTIONARY FILE UPDATES: 4 OCT 2000 HIGHEST RN 292819-21-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 11, 2000

Please note that search-term pricing does apply when conducting SmartSELECT searches.

Structure search limits have been increased. See HELP SLIMIT for details.

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 963

L1 SCREEN CREATED

=>
Uploading c:\stnexp4\queries\09543703.str

L2 STRUCTURE UPLOADED

=> que L2 AND L1

L3 QUE L2 AND L1

=> d l2

L2 HAS NO ANSWERS
L2 STR



G1 C,H,O,N

G2 N,OH

Structure attributes must be viewed using STN Express query preparation.

=> s l2 sss sam

SAMPLE SEARCH INITIATED 15:37:27 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 987 TO ITERATE

100.0% PROCESSED 987 ITERATIONS 50 ANSWERS
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 17856 TO 21624
PROJECTED ANSWERS: 801 TO 1759

L4 50 SEA SSS SAM L2

=> d scan l4

L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanoic acid, 2-[4-[2-[[(5-methoxy-1H-indol-2-yl)carbonyl]amino]ethyl]phenoxy]-2-methyl- (9CI)
MF C22 H24 N2 O5



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10

L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanoic acid, 2-[4-[[(3,5-dimethylphenyl)amino]carbonyl]phenoxy]-2-methyl- (9CI)
MF C19 H21 N O4



L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanoic acid, 2-[4-[2-[[[(2,4-difluorophenyl)amino]carbonyl]pentylamino]ethyl]phenoxy]-2-methyl- (9CI)
MF C24 H30 F2 N2 O4



L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanoic acid, 2-methyl-2-[4-[(phenylacetyl)amino]phenoxy]-, monosodium salt (9CI)
MF C18 H19 N O4 . Na



L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanoic acid, 2-[4-[2-[(2,6-dichlorophenyl)amino]-2-oxoethyl]phenoxy]-2-methyl-, monosodium salt (9CI)
MF C18 H17 Cl2 N O4 . Na



L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanoic acid, 2-[4-[2-[(2,3-dihydro-1H-inden-5-yl)amino]-2-oxoethyl]phenoxy]-2-methyl- (9CI)

MF C21 H23 N O4
CI COM



L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanoic acid, 2-[4-[2-[[[4-(acetylamino)phenyl]sulfonyl]amino]propyl]phenoxy]-2-methyl- (9CI)
MF C21 H26 N2 O6 S
CI COM



L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanamide, N-[3,5-dimethyl-4-[(nitromethyl)sulfonyl]phenyl]-2-methyl-2-phenoxy- (9CI)
MF C19 H22 N2 O6 S



L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanoic acid, 2-[4-[[[(4-formylphenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI)
MF C18 H18 N2 O5



L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanoic acid, 2-[4-[[[(4-chlorophenyl)amino]iminomethyl]amino]phenoxy]-2-methyl- (9CI)
MF C17 H18 Cl N3 O3



L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanamide, 2-(3,4-dimethylphenoxy)-2-methyl-N-4-pyridinyl- (9CI)
MF C17 H20 N2 O2



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10

L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN 4-Thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid, 3,3-dimethyl-6-(2-methyl-2-phenoxypropionamido)-7-oxo-, sodium salt (7CI)
MF C18 H22 N2 O5 S . Na

Absolute stereochemistry.



● Na

L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Ethanesulfonic acid, 2-[[2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-1-oxopropyl]amino]- (9CI)
MF C19 H20 Cl N O6 S
CI COM



L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanoic acid, 2-[2-chloro-4-[(hydroxyimino)-2-thienylmethyl]phenoxy]-2-methyl-, (Z)- (9CI)
MF C15 H14 Cl N O4 S

Double bond geometry as shown.



L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanoic acid, 2-[3-[(4-chlorophenoxy)methyl]phenoxy]-2-methyl- (9CI)
MF C17 H17 Cl O4



L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanoic acid, 2-[3-(3-bromobenzoyl)phenoxy]-2-methyl- (9CI)
MF C17 H15 Br O4



L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanoic acid, 2-[4-[2-cyano-2-[3-(trifluoromethyl)phenyl]ethenyl]phenoxy]-2-methyl- (9CI)
MF C20 H16 F3 N O3



L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanoic acid, 2-[4-[3-[[2-(2-chloro-6-fluorophenyl)ethyl][[(2,4-dimethoxyphenyl)amino]carbonyl]amino]propyl]phenoxy]-2-methyl- (9CI)
MF C30 H34 Cl F N2 O6



L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanoic acid, 2-[4-[2-[[[(4-fluorophenyl)amino]carbonyl](2-phenylethyl)amino]ethyl]phenoxy]-2-methyl- (9CI)
MF C27 H29 F N2 O4



L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanoic acid, 2-[4-[3-[(4-chlorophenyl)sulfonyl]propyl]-2-[[3-[[4-(1,1-dimethylethyl)-2-thiazolyl]methoxy]benzoyl]amino]phenoxy]-2-methyl- (9CI)

V. Balasubramanian

MF C34 H37 Cl N2 O7 S2



L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanamide, 2-[3,4-bis(chloromethyl)phenoxy]-N-(2-hydroxycyclohexyl)-2-methyl-, trans- (9CI)
MF C18 H25 Cl2 N O3

Relative stereochemistry.



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10

L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanoic acid, 2-[4-[[(3-chlorophenyl)acetyl]amino]phenoxy]-2-methyl-, monosodium salt (9CI)
MF C18 H18 Cl N O4 . Na



L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS

V. Balasubramanian

IN Propanoic acid, 2-methyl-2-[4-[2-[[(4-methylphenyl)sulfonyl]amino]propyl]phenoxy]-, (S)- (9CI)
MF C20 H25 N O5 S
CI COM

Absolute stereochemistry.



L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanoic acid, 2-[4-[2-[heptyl[[(2,4,6-trimethylphenyl)amino]carbonyl]amino]ethyl]phenoxy]-2-methyl- (9CI)
MF C29 H42 N2 O4



L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanamide, N,2-dimethyl-2-phenoxy- (9CI)
MF C11 H15 N O2



L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanoic acid, 2-[4-[[[(3-chlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI)
MF C17 H17 Cl N2 O4



L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Benzenesulfonic acid, 4-[[[[4-[[2-[4-(dodecyloxy)phenoxy]-2-methyl-1-oxopropyl]amino]-2-hydroxyphenyl]amino]carbonyl]amino]-, methyl ester (9CI)
MF C36 H49 N3 O8 S

PAGE 1-A



PAGE 1-B

—Me

L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanoic acid, 2-methyl-2-(2,3,5-trimethylphenoxy)- (9CI)
MF C13 H18 O3



L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanoic acid, 2-[5-[[2-[[(4-dodecylphenyl)sulfonyl]amino]-4-methyl-1-oxopentyl]amino]-3-fluoro-4-hydroxy-2-methylphenoxy]-2-methyl- (9CI)
MF C35 H53 F N2 O7 S



L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanamide, 2-[4-(4-chlorobenzoyl)phenoxy]-2-methyl-N-1-piperidinyl- (9CI)
MF C22 H25 Cl N2 O3



L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanoic acid, 2-[4-[(hydroxyimino)-2-thienylmethyl]phenoxy]-2-methyl-, (E)-, compd. with 2-aminoethanol (1:1) (9CI)
MF C15 H15 N O4 S . C2 H7 N O

CM 1

Double bond geometry as shown.



CM 2

$H_2N-CH_2-CH_2-OH$

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):10

L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanoic acid, 2-methyl-2-[4-[3-[(1-piperidinylcarbonyl)amino]propyl]phenoxy]- (9CI)
MF C19 H28 N2 O4
CI COM



L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanoic acid, 2-methyl-2-(4-phenoxyphenoxy)- (9CI)
MF C16 H16 O4



L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN 1-Imidazolidineacetamide, .alpha.-(2,2-dimethyl-1-oxopropyl)-N-[2-methoxy-5-[[2-methyl-2-(4-octylphenoxy)-1-oxopropyl]amino]phenyl]-2,5-dioxo-3-(2-phenylethyl)- (9CI)
MF C43 H56 N4 O7



L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanoic acid, 2-methyl-2-[4-[2-oxo-2-[(phenylmethyl)amino]ethyl]phenoxy]- (9CI)
MF C19 H21 N O4



L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanamide, 2-[2-[[[2-[4-(1,1-dimethylethyl)-2-thiazolyl]-5-benzofuranyl]oxy]methyl]phenoxy]-2-methyl- (9CI)
MF C26 H28 N2 O4 S



L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS

V. Balasubramanian

IN Propanoic acid, 2-[4-[[[(4-chlorophenyl)methyl]amino]carbonyl]phenoxy]-2-methyl-, monosodium salt (9CI)
MF C18 H18 Cl N O4 . Na



L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN L-Threonine, O-(1,1-dimethylethyl)-N-[2-methyl-2-(2-nitrophenoxy)-1-oxopropyl]- (9CI)
MF C18 H26 N2 O7

Absolute stereochemistry.



L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanoic acid, 2-methyl-2-[4-[[(phenylmethyl)amino]carbonyl]phenoxy]- (9CI)
MF C18 H19 N O4
CI COM



L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanoic acid, 2-[4-[2-[(butylsulfonyl)amino]propyl]phenoxy]-2-methyl-, monosodium salt (9CI)

V. Balasubramanian

MF C17 H27 N O5 S . Na



● Na

L4 50 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanoic acid, 2-[4-[[[[(2,4-dimethoxyphenyl)amino]carbonyl]pentylamino]methyl]phenoxy]-2-methyl- (9CI)
MF C25 H34 N2 O6



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.90	1.05

STN INTERNATIONAL LOGOFF AT 15:38:41 ON 05 OCT 2000

Trying 3106016892...Open

Welcome to STN International! Enter x:x
LOGINID:ssspta1611bxv
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

V. Balasubramanian

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

```
 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2  Aug 21  Instant Access to FDA Regulatory Information with
                  DIOGENES
 NEWS  3  Aug 21  CAS patent coverage expanded
 NEWS  4  Aug 24  TABULATE Now Available in More STN Databases
 NEWS  5  Aug 28  MEDLINE from 1958 to Date - Only on STN
 NEWS  6  Sep  7  DGENE GETSIM ALERT: Similarity Current-Awareness
                  Searching of Biosequences
 NEWS  7  Sep 11  Textile Technology Digest (TEXTILETECH) now available
                  on STN
 NEWS  8  Sep 21  KKF renamed DKILIT
 NEWS  9  Sep 29  The Philippines Inventory of Chemicals and Chemical
                  Substances (PICCS) has been added to CHEMLIST

 NEWS EXPRESS  FREE UPGRADE 5.0D FOR STN EXPRESS 5.0 WITH DISCOVER!
               (WINDOWS) NOW AVAILABLE
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

  All use of STN is subject to the provisions of the STN Customer
  agreement.  Please note that this agreement limits use to scientific
  research.  Use for software development or design or implementation
  of commercial gateways or other similar uses is prohibited and may
  result in loss of user privileges and other penalties.

  * * * * * * * * * * * * * * STN  Columbus  * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:52:45 ON 05 OCT 2000

=> file reg

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.15       0.15

FILE 'REGISTRY' ENTERED AT 15:52:50 ON 05 OCT 2000
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2000 American Chemical Society (ACS)

STRUCTURE FILE UPDATES:    4 OCT 2000  HIGHEST RN 292819-21-7
DICTIONARY FILE UPDATES:   4 OCT 2000  HIGHEST RN 292819-21-7

TSCA INFORMATION NOW CURRENT THROUGH JANUARY 11, 2000

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

Structure search limits have been increased.  See HELP SLIMIT
```

V. Balasubramanian

for details.

=> ....Testing the current file.... screen

ENTER SCREEN EXPRESSION OR (END):end

=> screen 963

L1 SCREEN CREATED

=>
Uploading c:\stnexp4\queries\09543703.str

L2 STRUCTURE UPLOADED

=> que L2 AND L1

L3 QUE L2 AND L1

=> d l2

L2 HAS NO ANSWERS
L2 STR









G1 C,H,O,N

G2 N,OH

G3 [@1],[@2],[@3]

Structure attributes must be viewed using STN Express query preparation.

V. Balasubramanian

=> s l2 sss sam

SAMPLE SEARCH INITIATED 15:53:35 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 7 TO ITERATE

100.0% PROCESSED 7 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 7 TO 298
PROJECTED ANSWERS: 3 TO 163

L4 3 SEA SSS SAM L2

=> d scan l4

L4 3 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanoic acid, 2-methyl-2-[4-[[[(3,4,5-trimethoxyphenyl)amino]carbonyl]amino]phenoxy]- (9CI)
MF C20 H24 N2 O7



HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):2

L4 3 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanoic acid, 2-[4-[[[(3-chlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI)
MF C17 H17 Cl N2 O4



L4 3 ANSWERS REGISTRY COPYRIGHT 2000 ACS
IN Propanoic acid, 2-[4-[[[(4-formylphenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI)
MF C18 H18 N2 O5



ALL ANSWERS HAVE BEEN SCANNED

=> s l2 sss ful

FULL SEARCH INITIATED 15:54:07 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 136 TO ITERATE

100.0% PROCESSED 136 ITERATIONS 63 ANSWERS
SEARCH TIME: 00.00.01

L5 63 SEA SSS FUL L2

=> file caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	126.60	126.75

FILE 'CAPLUS' ENTERED AT 15:54:17 ON 05 OCT 2000
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1967 - 5 Oct 2000 VOL 133 ISS 15
FILE LAST UPDATED: 4 Oct 2000 (20001004/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

Now you can extend your author, patent assignee, patent information, and title searches back to 1907. The records from 1907-1966 now have this searchable data in CAOLD. You now have electronic access to all of CA: 1907 to 1966 in CAOLD and 1967 to the present in CAPLUS on STN.

=> s l5

L6 19 L5

=> d l6 1-19 bib hitstr

L6 ANSWER 1 OF 19 CAPLUS COPYRIGHT 2000 ACS
AN 1999:697456 CAPLUS
DN 132:44918
TI Novel Inhibitors of Advanced Glycation Endproducts. [Erratum to document cited in CA131:317717]
AU Rahbar, Samuel; Yernini, Kiran Kumar V.; Scott, Stephen; Gonzales, Noe; Lalezari, Iraj
CS Dep. Diabetes, Endocrinology & Metabolism, City of Hope National Medical Center, Duarte, CA, 91010-0269, USA
SO Biochem. Biophys. Res. Commun. (1999), 264(3), 1008
CODEN: BBRCA9; ISSN: 0006-291X
PB Academic Press
DT Journal
LA English
IT **117011-50-4 121809-57-2 121809-58-3**
121809-65-2 121809-67-4 121809-68-5
121809-69-6 121809-70-9 121809-73-2
121809-74-3 121809-75-4 121809-77-6
121809-80-1 121809-82-3 121809-83-4
121809-84-5 121809-85-6 121809-89-0
121809-90-3 121809-94-7 157580-09-1
249513-62-0 249513-66-4 249513-67-5
249513-69-7 249513-70-0 249513-71-1
249513-72-2 249513-73-3 249513-74-4
249513-76-6 249513-77-7 249513-80-2
249513-81-3 249513-83-5 249513-84-6
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel inhibitors of advanced glycation endproducts (Erratum))
RN 117011-50-4 CAPLUS
CN Propanoic acid, 2-[4-[[[(3,4-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-57-2 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[[(phenylamino)carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 121809-58-3 CAPLUS
CN Propanoic acid, 2-[4-[(4-chlorobenzoyl)amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-65-2 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[[[(4-methylphenyl)amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 121809-67-4 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[[[(2,4,6-trimethylphenyl)amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 121809-68-5 CAPLUS
CN Propanoic acid, 2-[4-[[[(4-methoxyphenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-69-6 CAPLUS
CN Propanoic acid, 2-[4-[[[(3,4-dimethoxyphenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-70-9 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[[[(3,4,5-trimethoxyphenyl)amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 121809-73-2 CAPLUS
CN Propanoic acid, 2-[4-[[[(3,5-difluorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-74-3 CAPLUS
CN Propanoic acid, 2-[4-[[[(2-chlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-75-4 CAPLUS
CN Propanoic acid, 2-[4-[[[(3-chlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-77-6 CAPLUS
CN Propanoic acid, 2-[4-[[[(2,3-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-80-1 CAPLUS
CN Propanoic acid, 2-[4-[[[(3,5-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-82-3 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[[[(3,4,5-trichlorophenyl)amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 121809-83-4 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[[[(4-nitrophenyl)amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 121809-84-5 CAPLUS
CN Propanoic acid, 2-[4-[[[(2-chloro-5-nitrophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-85-6 CAPLUS
CN Propanoic acid, 2-[4-[[[(4-chloro-3-nitrophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-89-0 CAPLUS
CN Propanoic acid, 2-[4-[[[(4-formylphenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-90-3 CAPLUS
CN Propanoic acid, 2-[4-[[[[4-[(ethoxycarbonyl)amino]phenyl]amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-94-7 CAPLUS
CN Benzoic acid, 4-[[[[4-(1-carboxy-1-methylethoxy)phenyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 157580-09-1 CAPLUS
CN Propanoic acid, 2-[4-[[[(3-chloro-4-fluorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 249513-62-0 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[(2-naphthalenylcarbonyl)amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 249513-66-4 CAPLUS
CN L-Cystine, N,N'-bis[2-[4-[(4-chlorobenzoyl)amino]phenoxy]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 249513-67-5 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[[[2-[4-[[[(3,5-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl-1-oxopropyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 249513-69-7 CAPLUS
CN Cyclohexanecarboxylic acid, 1-[[2-[4-[[[(3,5-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)



RN 249513-70-0 CAPLUS
CN Propanoic acid, 2-[4-[[[(4-iodophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 249513-71-1 CAPLUS
CN Propanoic acid, 2-[4-[[[[4-(dimethylamino)phenyl]amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 249513-72-2 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[[[(2,4,6-trichlorophenyl)amino]carbonyl]ami

no]phenoxy]- (9CI) (CA INDEX NAME)



RN 249513-73-3 CAPLUS
CN Propanoic acid, 2-[4-[(4-chloro-3-nitrobenzoyl)amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 249513-74-4 CAPLUS
CN Propanoic acid, 2-[4-[[[(2-chloro-4-nitrophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 249513-76-6 CAPLUS
CN Propanoic acid, 2-[4-[(2,5-dichlorobenzoyl)amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 249513-77-7 CAPLUS
CN Propanoic acid, 2-[4-[(2,6-dichloro-4-nitrobenzoyl)amino]phenoxy]-2-methyl-

(9CI) (CA INDEX NAME)



RN 249513-80-2 CAPLUS
CN Propanoic acid, 2-[4-[(4-chloro-2-hydroxybenzoyl)amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 249513-81-3 CAPLUS
CN Propanoic acid, 2-[4-[(3,5-dichloro-2-hydroxybenzoyl)amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 249513-83-5 CAPLUS
CN Propanoic acid, 2,2'-[carbonylbis(imino-4,1-phenyleneoxy)]bis[2-methyl- (9CI) (CA INDEX NAME)



RN 249513-84-6 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[[[[4-(4-morpholinylsulfonyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



L6 ANSWER 2 OF 19 CAPLUS COPYRIGHT 2000 ACS
AN 1999:691824 CAPLUS
DN 132:81
TI A new rapid method to detect inhibition of Amadori product generated by .delta.-gluconolactone
AU Rahbar, Samuel; Nadler, Jerry L.
CS Department of Diabetes, Endocrinology and Metabolism, Gonda Diabetes Center, City of Hope National Medical Center, Duarte, CA, 91010, USA
SO Clin. Chim. Acta (1999), 287(1-2), 123-130
CODEN: CCATAR; ISSN: 0009-8981
PB Elsevier Science Ireland Ltd.
DT Journal
LA English
IT **121809-57-2 157580-09-1 249513-72-2**
249513-74-4
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(new rapid method to detect inhibition of Amadori product generated by .delta.-gluconolactone)
RN 121809-57-2 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[[(phenylamino)carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 157580-09-1 CAPLUS
CN Propanoic acid, 2-[4-[[[(3-chloro-4-fluorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 249513-72-2 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[[[(2,4,6-trichlorophenyl)amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 249513-74-4 CAPLUS
CN Propanoic acid, 2-[4-[[[(2-chloro-4-nitrophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RE.CNT 24
RE
(1) Bailey, A; Mech Aging Dev 1998, V106, P1 CAPLUS
(2) Baynes, J; Diabetes 1999, V48, P1 CAPLUS
(4) Booth, A; J Biol Chem 1997, V272, P5430 CAPLUS
(5) Brett, J; Am J Pathol 1993, V143, P1699 CAPLUS
(6) Bucala, R; Endocrinology cardiovascular function 1998, P159 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 3 OF 19 CAPLUS COPYRIGHT 2000 ACS
AN 1999:635489 CAPLUS
DN 131:262584
TI Modified hemoglobin and its use as a component of an artificial blood substitute
IN Lalezari, Iraj; Lalezari, Parviz
PA Montefiore Medical Center, USA
SO U.S., 22 pp., Cont. of U.S. Ser. No. 380,097, abandoned.
CODEN: USXXAM

V. Balasubramanian

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5962651	A	19991005	US 1997-903930	19970731
	US 6072072	A	20000606	US 1999-274072	19990322

PRAI US 1995-380097 19950127
US 1997-903930 19970731
OS MARPAT 131:262584
IT **121809-80-1P 245075-84-7P 245075-86-9P 245075-87-0P**
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation) (prepn. of functional compds. for Hb modification for blood substitutes)
RN 121809-80-1 CAPLUS
CN Propanoic acid, 2-[4-[[[(3,5-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 245075-84-7 CAPLUS
CN Propanoic acid, 2,2'-[methylenebis[(2-chloro-4,1-phenylene)iminocarbonylimino-4,1-phenyleneoxy]]bis[2-methyl- (9CI) (CA INDEX NAME)

PAGE 1-A



PAGE 1-B



RN 245075-86-9 CAPLUS
CN Pentanoic acid, 4-[[2-[4-[[[(3,5-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl-1-oxopropyl]amino]-5-[(2,5-dioxo-1-pyrrolidinyl)oxy]-5-oxo-, (4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 245075-87-0 CAPLUS
CN L-Aspartic acid, N-[2-[4-[[[(3,5-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl-1-oxopropyl]-, 1-(phenylmethyl) ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RE.CNT 4
RE
(1) Abraham; US 5122539 1992 CAPLUS
(2) Calezari; US 5268500 1993
(3) Fronticelli; US 5239061 1993
(4) Hoffman; US 5028588 1991

L6 ANSWER 4 OF 19 CAPLUS COPYRIGHT 2000 ACS
AN 1999:558280 CAPLUS
DN 131:317717
TI Novel Inhibitors of Advanced Glycation Endproducts
AU Rahbar, Samuel; Kumar Yernini, Kiran; Scott, Stephen; Gonzales, Noe; Lalezari, Iraj
CS Department of Diabetes, Endocrinology & Metabolism, City of Hope National Medical Center, Duarte, CA, 91010-0269, USA
SO Biochem. Biophys. Res. Commun. (1999), 262(3), 651-656
CODEN: BBRCA9; ISSN: 0006-291X
PB Academic Press
DT Journal
LA English

IT **117011-50-4 121809-57-2 121809-58-3**
121809-65-2 121809-67-4 121809-68-5
121809-69-6 121809-70-9 121809-73-2
121809-74-3 121809-75-4 121809-77-6
121809-80-1 121809-82-3 121809-83-4
121809-84-5 121809-85-6 121809-89-0
121809-90-3 121809-94-7 157580-09-1
249513-62-0 249513-66-4 249513-67-5
249513-69-7 249513-70-0 249513-71-1
249513-72-2 249513-73-3 249513-74-4
249513-76-6 249513-77-7 249513-80-2
249513-81-3 249513-83-5 249513-84-6
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel inhibitors of advanced glycation endproducts)

RN 117011-50-4 CAPLUS
CN Propanoic acid, 2-[4-[[[(3,4-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-57-2 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[[(phenylamino)carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 121809-58-3 CAPLUS
CN Propanoic acid, 2-[4-[(4-chlorobenzoyl)amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-65-2 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[[[(4-methylphenyl)amino]carbonyl]amino]phen

oxy]- (9CI) (CA INDEX NAME)



RN 121809-67-4 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[[[(2,4,6-trimethylphenyl)amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 121809-68-5 CAPLUS
CN Propanoic acid, 2-[4-[[[(4-methoxyphenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-69-6 CAPLUS
CN Propanoic acid, 2-[4-[[[(3,4-dimethoxyphenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-70-9 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[[[(3,4,5-trimethoxyphenyl)amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 121809-73-2 CAPLUS
CN Propanoic acid, 2-[4-[[[(3,5-difluorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-74-3 CAPLUS
CN Propanoic acid, 2-[4-[[[(2-chlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-75-4 CAPLUS
CN Propanoic acid, 2-[4-[[[(3-chlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-77-6 CAPLUS
CN Propanoic acid, 2-[4-[[[(2,3-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-80-1 CAPLUS
CN Propanoic acid, 2-[4-[[[(3,5-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-82-3 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[[[(3,4,5-trichlorophenyl)amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 121809-83-4 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[[[(4-nitrophenyl)amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 121809-84-5 CAPLUS
CN Propanoic acid, 2-[4-[[[(2-chloro-5-nitrophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-85-6 CAPLUS
CN Propanoic acid, 2-[4-[[[(4-chloro-3-nitrophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-89-0 CAPLUS
CN Propanoic acid, 2-[4-[[[(4-formylphenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-90-3 CAPLUS
CN Propanoic acid, 2-[4-[[[[4-[(ethoxycarbonyl)amino]phenyl]amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-94-7 CAPLUS
CN Benzoic acid, 4-[[[[4-(1-carboxy-1-methylethoxy)phenyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



RN 157580-09-1 CAPLUS
CN Propanoic acid, 2-[4-[[[(3-chloro-4-fluorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 249513-62-0 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[(2-naphthalenylcarbonyl)amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 249513-66-4 CAPLUS
CN L-Cystine, N,N'-bis[2-[4-[(4-chlorobenzoyl)amino]phenoxy]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



RN 249513-67-5 CAPLUS
CN Cyclohexanecarboxylic acid, 4-[[[2-[4-[[[(3,5-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl-1-oxopropyl]amino]methyl]- (9CI) (CA INDEX NAME)



RN 249513-69-7 CAPLUS
CN Cyclohexanecarboxylic acid, 1-[[2-[4-[[[(3,5-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl-1-oxopropyl]amino]- (9CI) (CA INDEX NAME)



RN 249513-70-0 CAPLUS
CN Propanoic acid, 2-[4-[[[(4-iodophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 249513-71-1 CAPLUS
CN Propanoic acid, 2-[4-[[[[4-(dimethylamino)phenyl]amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 249513-72-2 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[[[(2,4,6-trichlorophenyl)amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 249513-73-3 CAPLUS
CN Propanoic acid, 2-[4-[(4-chloro-3-nitrobenzoyl)amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 249513-74-4 CAPLUS
CN Propanoic acid, 2-[4-[[[(2-chloro-4-nitrophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 249513-76-6 CAPLUS
CN Propanoic acid, 2-[4-[(2,5-dichlorobenzoyl)amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 249513-77-7 CAPLUS
CN Propanoic acid, 2-[4-[(2,6-dichloro-4-nitrobenzoyl)amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 249513-80-2 CAPLUS
CN Propanoic acid, 2-[4-[(4-chloro-2-hydroxybenzoyl)amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 249513-81-3 CAPLUS
CN Propanoic acid, 2-[4-[(3,5-dichloro-2-hydroxybenzoyl)amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 249513-83-5 CAPLUS
CN Propanoic acid, 2,2'-[carbonylbis(imino-4,1-phenyleneoxy)]bis[2-methyl- (9CI) (CA INDEX NAME)



RN 249513-84-6 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[[[[4-(4-morpholinylsulfonyl)phenyl]amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 48
RE
(1) Al-Abed, Y; J Biol Chem 1996, V271, P2892 CAPLUS

(4) Baynes, J; Diabetes 1999, V48, P1 CAPLUS
(5) Beisswenger, P; Diabetes 1999, V48, P198 CAPLUS
(7) Booth, A; J Biol Chem 1997, V272, P5430 CAPLUS
(8) Brownlee, M; Science 1986, V232, P1629 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 5 OF 19 CAPLUS COPYRIGHT 2000 ACS
AN 1999:19928 CAPLUS
DN 130:217602
TI Structure/function of allosteric effectors of hemoglobin
AU Abraham, Donald J.; Kister, Jean; Joshi, Gajanan S.; Wireko, Fred C.; Safo, Martin K.; Marden, Michael C.; Poyart, Claude
CS Institute for Structural Biology and Drug Discovery, and Department of Medicinal Chemistry, Virginia Commonwealth University, Richmond, VA, 23298, USA
SO Med. Chem. Res. (1998), 8(7/8), 478-486
CODEN: MCREEB; ISSN: 1054-2523
PB Birkhaeuser Boston
DT Journal
LA English
IT **117011-50-4 121809-80-1**, L 35 **121809-82-3**
RL: BAC (Biological activity or effector, except adverse); PRP (Properties); BIOL (Biological study)
(structure/function of allosteric effectors of Hb)
RN 117011-50-4 CAPLUS
CN Propanoic acid, 2-[4-[[[(3,4-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-80-1 CAPLUS
CN Propanoic acid, 2-[4-[[[(3,5-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-82-3 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[[[(3,4,5-trichlorophenyl)amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RE.CNT 19
RE
(1) Abraham, D; Biochem 1992, V31, P9141 CAPLUS
(2) Abraham, D; Blood 1991, V77, P1334 CAPLUS
(3) Abraham, D; J Mol Biol 1995, V248, P845 CAPLUS
(4) Abraham, D; Proc Natl Acad Sci 1983, V80, P324 CAPLUS
(6) Arnone, A; Nature 1972, V237, P146 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 6 OF 19 CAPLUS COPYRIGHT 2000 ACS
AN 1998:207267 CAPLUS
DN 128:270438
TI Preparation of phenoxypropionic acids and analogs as hemoglobin allosteric modifiers
IN Abraham, Donald J.; Joshi, Gajanan; Randad, Ramnarayan; Panikker, Jayashree
PA Virginia Commonwealth University, USA
SO U.S., 43 pp. Cont.-in-part of U.S. 5,432,191.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5731454	A	19980324	US 1995-374206	19950118
	US 5049695	A	19910917	US 1990-478848	19900212
	US 5122539	A	19920616	US 1991-702947	19910520
	US 5382680	A	19950117	US 1991-722382	19910626
	US 5290803	A	19940301	US 1993-6246	19930119
	US 5432191	A	19950711	US 1993-101501	19930730
	US 5591892	A	19970107	US 1995-451658	19950530
	US 5648375	A	19970715	US 1995-478372	19950607
	US 5677330	A	19971014	US 1995-478371	19950607
	US 5705521	A	19980106	US 1995-482808	19950607
	US 5927283	A	19990727	US 1997-848485	19970508
	US 5872282	A	19990216	US 1998-41595	19980313

PRAI	US 1990-623346	19901207
	US 1990-478848	19901212
	US 1991-702947	19910520
	US 1991-722382	19910626
	US 1993-6246	19930119
	US 1993-101501	19930730
	US 1992-885721	19920518
	US 1995-374206	19950118
	US 1995-478371	19950607

OS MARPAT 128:270438
IT **121809-80-1P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic

preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of phenoxypropionic acids and analogs as Hb allosteric modifiers)
RN 121809-80-1 CAPLUS
CN Propanoic acid, 2-[4-[[[(3,5-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



L6 ANSWER 7 OF 19 CAPLUS COPYRIGHT 2000 ACS
AN 1998:41719 CAPLUS
DN 128:110865
TI Use of allosteric hemoglobin modifiers in combination with radiation therapy to treat carcinogenic tumors
IN Abraham, Donald J.
PA Center for Innovative Technology, USA
SO U.S., 47 pp. Cont.-in-part of U.S. Ser. No. 374,206.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5705521	A	19980106	US 1995-482808	19950607
	US 5049695	A	19910917	US 1990-478848	19900212
	US 5122539	A	19920616	US 1991-702947	19910520
	US 5382680	A	19950117	US 1991-722382	19910626
	US 5290803	A	19940301	US 1993-6246	19930119
	US 5432191	A	19950711	US 1993-101501	19930730
	US 5731454	A	19980324	US 1995-374206	19950118
PRAI	US 1990-478848	19900212			
	US 1990-623346	19901207			
	US 1991-702947	19910520			
	US 1991-722382	19910626			
	US 1993-6246	19930119			
	US 1993-101501	19930730			
	US 1995-374206	19950118			
	US 1992-885721	19920518			

OS MARPAT 128:110865
IT **121809-80-1**
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(allosteric Hb modifiers in combination with radiation therapy to treat carcinogenic tumors, prepn., and use for other oxygen tension-related diseases)
RN 121809-80-1 CAPLUS
CN Propanoic acid, 2-[4-[[[(3,5-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



L6 ANSWER 8 OF 19 CAPLUS COPYRIGHT 2000 ACS
AN 1997:693601 CAPLUS
DN 127:336654
TI Medical uses of allosteric hemoglobin modifier compounds in patient care
IN Abraham, Donald J.; Gerber, Michael
PA Center for Innovative Technology, USA; Allos Therapeutics, Inc.
SO U.S., 48 pp. Cont.-in-part of U.S. 5,382,680.
CODEN: USXXAM
DT Patent
LA English
FAN.CNT 8

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 5677330	A	19971014	US 1995-478371	19950607
	US 5049695	A	19910917	US 1990-478848	19900212
	US 5122539	A	19920616	US 1991-702947	19910520
	US 5382680	A	19950117	US 1991-722382	19910626
	US 5290803	A	19940301	US 1993-6246	19930119
	US 5432191	A	19950711	US 1993-101501	19930730
	US 5731454	A	19980324	US 1995-374206	19950118
	US 5927283	A	19990727	US 1997-848485	19970508
PRAI	US 1990-478848	19900212			
	US 1990-623346	19901207			
	US 1991-702947	19910520			
	US 1991-722382	19910626			
	US 1993-6246	19930119			
	US 1993-101501	19930730			
	US 1995-374206	19950118			
	US 1992-885721	19920518			
	US 1995-478371	19950607			

OS MARPAT 127:336654
IT **121809-80-1P**
RL: BAC (Biological activity or effector, except adverse); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(allosteric Hb modifier compds.)
RN 121809-80-1 CAPLUS
CN Propanoic acid, 2-[4-[[[(3,5-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



L6 ANSWER 9 OF 19 CAPLUS COPYRIGHT 2000 ACS
AN 1994:579000 CAPLUS
DN 121:179000
TI 13C NMR spectra of allosteric effectors of hemoglobin
AU Ostrowski, Stanislaw; Priebe, Waldemar; Burke, Thomas G.
CS M. D. Anderson Cancer Cent., Univ. Texas, Houston, TX, 77030, USA
SO Magn. Reson. Chem. (1994), 32(3), 182-3
CODEN: MRCHEG; ISSN: 0749-1581
DT Journal
LA English
IT **117011-50-4 121809-75-4 121809-83-4**
157579-93-6 157579-95-8 157579-96-9
157579-99-2 157580-01-3 157580-02-4
157580-04-6 157580-05-7 157580-07-9
157580-09-1 157580-14-8 157580-16-0
157580-19-3
RL: PRP (Properties)
(NMR of carbon-13 of)
RN 117011-50-4 CAPLUS
CN Propanoic acid, 2-[4-[[[(3,4-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-75-4 CAPLUS
CN Propanoic acid, 2-[4-[[[(3-chlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-83-4 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[[[(4-nitrophenyl)amino]carbonyl]amino]pheno

xy]- (9CI) (CA INDEX NAME)



RN 157579-93-6 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[[[(2-methyl-5-nitrophenyl)amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 157579-95-8 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[[[(3-nitrophenyl)amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 157579-96-9 CAPLUS
CN Propanoic acid, 2-[4-[[[(3-aminophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 157579-99-2 CAPLUS
CN Propanoic acid, 2-[4-[[[(4-aminophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 157580-01-3 CAPLUS
CN Propanoic acid, 2-[4-[[[(2-methoxy-4-nitrophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 157580-02-4 CAPLUS
CN Propanoic acid, 2-[4-[[[(4-amino-2-methoxyphenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 157580-04-6 CAPLUS
CN Propanoic acid, 2-[4-[[[(4-fluoro-3-nitrophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 157580-05-7 CAPLUS
CN Propanoic acid, 2-[4-[[[(3-amino-4-fluorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 157580-07-9 CAPLUS
CN Propanoic acid, 2-[4-[[[(2-fluoro-5-nitrophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 157580-09-1 CAPLUS
CN Propanoic acid, 2-[4-[[[(3-chloro-4-fluorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 157580-14-8 CAPLUS
CN Propanoic acid, 2-[4-[[[(3-cyanophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 157580-16-0 CAPLUS
CN Propanoic acid, 2-[4-[[[(4-cyanophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 157580-19-3 CAPLUS
CN Propanoic acid, 2-[4-[[[[3,5-bis(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



L6 ANSWER 10 OF 19 CAPLUS COPYRIGHT 2000 ACS
AN 1993:455833 CAPLUS
DN 119:55833
TI Evaluation of LEH/LR16 artificial blood formulation
AU Burke, T. G.; Staubus, A. E.
CS Coll. Pharm., Ohio State Univ., Columbus, OH, USA
SO Report (1992), Order No. AD-A248575, 10 pp. Avail.: NTIS
From: Gov. Rep. Announce. Index (U. S.) 1992, 92(15), Abstr. No. 240,053
DT Report
LA English
IT **117011-50-4D**, LR 16, analogs
RL: BIOL (Biological study)
(liposomes contg. Hbs and, for blood substitutes)
RN 117011-50-4 CAPLUS
CN Propanoic acid, 2-[4-[[[(3,4-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



L6 ANSWER 11 OF 19 CAPLUS COPYRIGHT 2000 ACS
AN 1991:639430 CAPLUS
DN 115:239430
TI Evaluation of liposome-encapsulated hemoglobin/LR16 formulation as a potential blood substitute
AU Burke, T. G.
CS City of Hope Natl. Med. Cent., Duarte, CA, USA

V. Balasubramanian

SO Report (1990), Order No. AD-A229 090, 9 pp. Avail.: NTIS
From: Gov. Rep. Announce. Index (U. S.) 1991, 91(10), Abstr. No. 124,831
DT Report
LA English
IT **117011-50-4**, LR 16
RL: BIOL (Biological study)
(liposomes contg. Hb and, for blood substitutes)
RN 117011-50-4 CAPLUS
CN Propanoic acid, 2-[4-[[[(3,4-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



L6 ANSWER 12 OF 19 CAPLUS COPYRIGHT 2000 ACS
AN 1991:77296 CAPLUS
DN 114:77296
TI Allosteric modifiers of hemoglobin. 2. Crystallographically determined binding sites and hydrophobic binding/interaction analysis of novel hemoglobin oxygen effectors
AU Wireko, Fred C.; Kellogg, Glen E.; Abraham, Donald J.
CS Med. Coll. Virginia, Virginia Commonw. Univ., Richmond, VA, 23298-0581, USA
SO J. Med. Chem. (1991), 34(2), 758-67
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
IT **117011-50-4 121809-80-1 121809-82-3**
RL: BIOL (Biological study)
(Hb of human binding by, hydrophobicity in and oxygen binding response to and allosteric modifier structure relation to)
RN 117011-50-4 CAPLUS
CN Propanoic acid, 2-[4-[[[(3,4-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-80-1 CAPLUS
CN Propanoic acid, 2-[4-[[[(3,5-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-82-3 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[[[(3,4,5-trichlorophenyl)amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



L6 ANSWER 13 OF 19 CAPLUS COPYRIGHT 2000 ACS
AN 1990:536008 CAPLUS
DN 113:136008
TI Effect of nonionic surfactants on chalcopyrite leaching under dump chemical conditions
AU Sandoval, S. P.; Pool, D. L.; Schultze, L. E.
CS Reno Res. Cent., U. S. Bur. Mines, Reno, NV, USA
SO Bur. Mines Rep. Invest. (1990), RI 9311, 16 pp.
CODEN: XBMIA6; ISSN: 0096-1922
DT Report
LA English
IT **121809-80-1**, L35
RL: PROC (Process)
(surfactant, leaching of copper from chalcopyrite with ferric sulfate soln. contg. nonionic)
RN 121809-80-1 CAPLUS
CN Propanoic acid, 2-[4-[[[(3,5-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



L6 ANSWER 14 OF 19 CAPLUS COPYRIGHT 2000 ACS
AN 1990:423397 CAPLUS
DN 113:23397

V. Balasubramanian

TI Preparation of (arylureidophenoxy)- and (benzamidophenoxy)methylpropionic acid derivatives which reduce the affinity of hemoglobin for oxygen
IN Lalezari, Iraj; Lalezari, Parviz
PA USA
SO PCT Int. Appl., 32 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 8912622	A1	19891228	WO 1989-US2621	19890615
	W: JP				
	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	US 4921997	A	19900501	US 1988-207098	19880615
	EP 420930	A1	19910410	EP 1989-907939	19890615
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 03505728	T2	19911212	JP 1989-507363	19890615
	US 5093367	A	19920303	US 1990-477048	19900207
	US 5292935	A	19940308	US 1992-821409	19920115
	US 5472981	A	19951205	US 1993-158702	19931129
PRAI	US 1988-207098	19880615			
	WO 1989-US2621	19890615			
	US 1990-477048	19900207			
	US 1992-821409	19920115			

OS MARPAT 113:23397
IT **121809-78-7 121809-79-8**
RL: RCT (Reactant)
(Hb-oxygen affinity, effect on)
RN 121809-78-7 CAPLUS
CN Propanoic acid, 2-[4-[[[(2,4-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-79-8 CAPLUS
CN Propanoic acid, 2-[4-[[[(2,5-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



IT **117011-50-4P 121809-73-2P 121809-80-1P**
121809-81-2P 121809-82-3P 121809-91-4P
127676-57-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as Hb-oxygen affinity-reducing agent)

RN 117011-50-4 CAPLUS
CN Propanoic acid, 2-[4-[[[(3,4-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-73-2 CAPLUS
CN Propanoic acid, 2-[4-[[[(3,5-difluorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-80-1 CAPLUS
CN Propanoic acid, 2-[4-[[[(3,5-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-81-2 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[[[(2,4,5-trichlorophenyl)amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 121809-82-3 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[[[(3,4,5-trichlorophenyl)amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 121809-91-4 CAPLUS
CN Propanoic acid, 2-[4-[(3,5-dichlorobenzoyl)amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 127676-57-7 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[[[(2,3,4-trichlorophenyl)amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



L6 ANSWER 15 OF 19 CAPLUS COPYRIGHT 2000 ACS
AN 1990:231450 CAPLUS
DN 112:231450
TI Effectors of hemoglobin. Separation of allosteric and affinity factors
AU Marden, Michael C.; Bohn, Brigitte; Kister, Jean; Poyart, Claude

V. Balasubramanian

CS Hop. Bicetre, Le Kremlin Bicetre, 94275, Fr.
SO Biophys. J. (1990), 57(3), 397-403
CODEN: BIOJAU; ISSN: 0006-3495
DT Journal
LA English
IT **117011-50-4 121809-80-1**, L 35
RL: BIOL (Biological study)
(Hb binding by carbon monoxide and oxygen response to, effectors affinity and allosterism in)
RN 117011-50-4 CAPLUS
CN Propanoic acid, 2-[4-[[[(3,4-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-80-1 CAPLUS
CN Propanoic acid, 2-[4-[[[(3,5-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



L6 ANSWER 16 OF 19 CAPLUS COPYRIGHT 2000 ACS
AN 1990:72472 CAPLUS
DN 112:72472
TI New effectors of human hemoglobin: structure and function
AU Lalezari, I.; Lalezari, P.; Poyart, C.; Marden, M.; Kister, J.; Bohn, B.; Fermi, G.; Perutz, M. F.
CS Montefiore Med. Cent., Albert Einstein Coll. Med., Bronx, NY, 10467, USA
SO Biochemistry (1990), 29(6), 1515-23
CODEN: BICHAW; ISSN: 0006-2960
DT Journal
LA English
IT **117011-50-4**, LR16
RL: BIOL (Biological study)
(as Hb A of human allosteric effector, methylpropionic acid derivs. compared to)
RN 117011-50-4 CAPLUS
CN Propanoic acid, 2-[4-[[[(3,4-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



IT **121809-80-1 121809-82-3**
RL: PROC (Process)
(as Hb A of human allosteric effector, structure and function of)
RN 121809-80-1 CAPLUS
CN Propanoic acid, 2-[4-[[[(3,5-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-82-3 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[[[(3,4,5-trichlorophenyl)amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



L6 ANSWER 17 OF 19 CAPLUS COPYRIGHT 2000 ACS
AN 1989:587608 CAPLUS
DN 111:187608
TI Compound, composition, and method for the reduction of lipids, the modification of the affinity of hemoglobin for oxygen, and the prevention of platelet aggregation
IN Lalezari, Iraj; Rahbar, Samuel; Lalezari, Parviz
PA USA
SO PCT Int. Appl., 15 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 8810113	A1	19881229	WO 1988-US2092	19880615
W: AU, JP				

	RW: AT, BE, CH, DE, FR, GB, IT, LU, NL, SE				
	AU 8819986	A1	19890119	AU 1988-19986	19880615
	AU 616674	B2	19911107		
	EP 358724	A1	19900321	EP 1988-906435	19880615
	R: AT, BE, CH, DE, FR, GB, IT, LI, LU, NL, SE				
	JP 02503797	T2	19901108	JP 1988-505967	19880615
	US 5268500	A	19931207	US 1991-778706	19911018
PRAI	US 1987-62236	19870615			
	WO 1988-US2092	19880615			
	US 1989-327020	19890322			
	US 1990-515673	19900412			
	US 1991-658096	19910220			

OS MARPAT 111:187608

IT **117011-50-4P 121809-57-2P 121809-76-5P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. of, as antihyperlipidemic and for modification of oxygen affinity of Hb)

RN 117011-50-4 CAPLUS

CN Propanoic acid, 2-[4-[[[(3,4-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-57-2 CAPLUS

CN Propanoic acid, 2-methyl-2-[4-[[(phenylamino)carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 121809-76-5 CAPLUS

CN Propanoic acid, 2-[4-[[[(4-chlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



L6 ANSWER 18 OF 19 CAPLUS COPYRIGHT 2000 ACS
AN 1989:533730 CAPLUS
DN 111:133730
TI Synthesis and investigation of effects of 2-[4-[[(arylamino)carbonyl]amino]phenoxy]-2-methylpropionic acids on the affinity of hemoglobin for oxygen: structure-activity relationships
AU Lalezari, Iraj; Lalezari, Parviz
CS Dep. Med., Montefiore Med. Cent., Bronx, NY, 10467, USA
SO J. Med. Chem. (1989), 32(10), 2352-7
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English
OS CASREACT 111:133730
IT **117011-50-4 121809-77-6 121809-78-7**
121809-79-8 121809-80-1 121809-81-2
121809-82-3 121809-83-4 121809-84-5
121809-85-6 121809-86-7 121809-87-8
RL: RCT (Reactant)
(prepn. and Hb-oxygen affinity in presence of)
RN 117011-50-4 CAPLUS
CN Propanoic acid, 2-[4-[[[(3,4-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-77-6 CAPLUS
CN Propanoic acid, 2-[4-[[[(2,3-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-78-7 CAPLUS
CN Propanoic acid, 2-[4-[[[(2,4-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-79-8 CAPLUS
CN Propanoic acid, 2-[4-[[[(2,5-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-80-1 CAPLUS
CN Propanoic acid, 2-[4-[[[(3,5-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-81-2 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[[[(2,4,5-trichlorophenyl)amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 121809-82-3 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[[[(3,4,5-trichlorophenyl)amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 121809-83-4 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[[[(4-nitrophenyl)amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 121809-84-5 CAPLUS
CN Propanoic acid, 2-[4-[[[(2-chloro-5-nitrophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-85-6 CAPLUS
CN Propanoic acid, 2-[4-[[[(4-chloro-3-nitrophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-86-7 CAPLUS
CN Propanoic acid, 2-[4-[[[(2-hydroxyphenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-87-8 CAPLUS
CN Propanoic acid, 2-[4-[[[(4-hydroxyphenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



IT **121809-57-2P 121809-58-3P 121809-65-2P**
121809-66-3P 121809-67-4P 121809-68-5P
121809-69-6P 121809-70-9P 121809-71-0P
121809-72-1P 121809-73-2P 121809-74-3P
121809-75-4P 121809-76-5P 121809-88-9P
121809-89-0P 121809-90-3P 121809-91-4P
121809-94-7P
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and Hb-oxygen affinity in the presence of)
RN 121809-57-2 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[[(phenylamino)carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 121809-58-3 CAPLUS
CN Propanoic acid, 2-[4-[(4-chlorobenzoyl)amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-65-2 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[[[(4-methylphenyl)amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 121809-66-3 CAPLUS
CN Propanoic acid, 2-[4-[[[(3,4-dimethylphenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-67-4 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[[[(2,4,6-trimethylphenyl)amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 121809-68-5 CAPLUS
CN Propanoic acid, 2-[4-[[[(4-methoxyphenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-69-6 CAPLUS
CN Propanoic acid, 2-[4-[[[(3,4-dimethoxyphenyl)amino]carbonyl]amino]phenoxy]-

2-methyl- (9CI) (CA INDEX NAME)



RN 121809-70-9 CAPLUS
CN Propanoic acid, 2-methyl-2-[4-[[[(3,4,5-trimethoxyphenyl)amino]carbonyl]amino]phenoxy]- (9CI) (CA INDEX NAME)



RN 121809-71-0 CAPLUS
CN Propanoic acid, 2-[4-[[(1,3-benzodioxol-5-ylamino)carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-72-1 CAPLUS
CN Propanoic acid, 2-[4-[[[(4-fluorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-73-2 CAPLUS
CN Propanoic acid, 2-[4-[[[(3,5-difluorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-74-3 CAPLUS
CN Propanoic acid, 2-[4-[[[(2-chlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-75-4 CAPLUS
CN Propanoic acid, 2-[4-[[[(3-chlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-76-5 CAPLUS
CN Propanoic acid, 2-[4-[[[(4-chlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-88-9 CAPLUS
CN Propanoic acid, 2-[4-[[[[4-(acetyloxy)phenyl]amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-89-0 CAPLUS
CN Propanoic acid, 2-[4-[[[(4-formylphenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-90-3 CAPLUS
CN Propanoic acid, 2-[4-[[[[4-[(ethoxycarbonyl)amino]phenyl]amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-91-4 CAPLUS
CN Propanoic acid, 2-[4-[(3,5-dichlorobenzoyl)amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



RN 121809-94-7 CAPLUS
CN Benzoic acid, 4-[[[[4-(1-carboxy-1-methylethoxy)phenyl]amino]carbonyl]amino]- (9CI) (CA INDEX NAME)



L6 ANSWER 19 OF 19 CAPLUS COPYRIGHT 2000 ACS
AN 1988:563263 CAPLUS
DN 109:163263
TI LR16, a compound with potent effects on the oxygen affinity of hemoglobin, on blood cholesterol, and on low density lipoprotein
AU Lalezari, I.; Rahbar, S.; Lalezari, P.; Fermi, G.; Perutz, M. F.
CS Dep. Anesthesiol., Montefiore Med. cent., Bronx, NY, 10467, USA
SO Proc. Natl. Acad. Sci. U. S. A. (1988), 85(16), 6117-21
CODEN: PNASA6; ISSN: 0027-8424
DT Journal
LA English
IT **117011-50-4P**
RL: SPN (Synthetic preparation); PREP (Preparation)
(prepn. and anticholesterolemic activity of and Hb oxygen affinity response to)
RN 117011-50-4 CAPLUS
CN Propanoic acid, 2-[4-[[[(3,4-dichlorophenyl)amino]carbonyl]amino]phenoxy]-2-methyl- (9CI) (CA INDEX NAME)



=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	53.21	179.96

STN INTERNATIONAL LOGOFF AT 15:56:19 ON 05 OCT 2000

Trying 3106016892...Open

Welcome to STN International! Enter x:x
LOGINID:ssspta1611bxv
PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

V. Balasubramanian

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

```
 NEWS  1          Web Page URLs for STN Seminar Schedule - N. America
 NEWS  2  Dec 17  The CA Lexicon available in the CAPLUS and CA files
 NEWS  3  Feb 06  Engineering Information Encompass files have new names
 NEWS  4  Feb 16  TOXLINE no longer being updated
 NEWS  5  Apr 23  Search Derwent WPINDEX by chemical structure
 NEWS  6  Apr 23  PRE-1967 REFERENCES NOW SEARCHABLE IN CAPLUS AND CA
 NEWS  7  May 07  DGENE Reload
 NEWS  8  Jun 20  Published patent applications (A1) are now in USPATFULL
 NEWS  9  JUL 13  New SDI alert frequency now available in Derwent's
                  DWPI and DPCI
 NEWS 10  Aug 23  In-process records and more frequent updates now in
                  MEDLINE
 NEWS 11  Aug 23  PAGE IMAGES FOR 1947-1966 RECORDS IN CAPLUS AND CA
 NEWS 12  Aug 23  Adis Newsletters (ADISNEWS) now available on STN
 NEWS 13  Sep 17  IMSworld Pharmaceutical Company Directory name change
                  to PHARMASEARCH

 NEWS EXPRESS  August 15 CURRENT WINDOWS VERSION IS V6.0c,
               CURRENT MACINTOSH VERSION IS V6.0 (ENG) AND V6.0J (JP),
               AND CURRENT DISCOVER FILE IS DATED 07 AUGUST 2001
 NEWS HOURS    STN Operating Hours Plus Help Desk Availability
 NEWS INTER    General Internet Information
 NEWS LOGIN    Welcome Banner and News Items
 NEWS PHONE    Direct Dial and Telecommunication Network Access to STN
 NEWS WWW      CAS World Wide Web Site (general information)
```

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

```
FILE 'HOME' ENTERED AT 14:20:49 ON 23 SEP 2001

=> file caplus
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.15       0.15

FILE 'CAPLUS' ENTERED AT 14:20:58 ON 23 SEP 2001
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2001 AMERICAN CHEMICAL SOCIETY (ACS)
```

26, 1996), unless otherwise indicated in the original publications.

FILE COVERS 1947 - 23 Sep 2001 VOL 135 ISS 14
FILE LAST UPDATED: 21 Sep 2001 (20010921/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

This file supports REG1stRY for direct browsing and searching of all substance data from the REGISTRY file. Enter HELP FIRST for more information.

CAplus now provides online access to patents and literature covered in CA from 1947 to the present. On April 22, 2001, bibliographic information and abstracts were added for over 2.2 million references published in CA from 1947 to 1966.

The CA Lexicon is now available in the Controlled Term (/CT) field. Enter HELP LEXICON for full details.


```
=> s advanced(l)glycation(l)ednproduct?
         71854 ADVANCED
          2722 GLYCATION
             0 EDNPRODUCT?
L1           0 ADVANCED(L)GLYCATION(L)EDNPRODUCT?

=> s advanced(l)glycation(l)endproduct?
         71854 ADVANCED
          2722 GLYCATION
           571 ENDPRODUCT?
L2         233 ADVANCED(L)GLYCATION(L)ENDPRODUCT?

=> l2 and acid
L2 IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> s l2 and acid
       3008179 ACID
L3           35 L2 AND ACID

=> d scan l3

L3    35 ANSWERS   CAPLUS  COPYRIGHT 2001 ACS
CC    14-11 (Mammalian Pathological Biochemistry)
      Section cross-reference(s): 2, 15
TI    The receptor for advanced glycation end products mediates the chemotaxis
      of rabbit smooth muscle cells
ST    advanced glycation endproduct receptor
      smooth muscle; AGE receptor vascular smooth muscle atherosclerosis;
      TGFbeta AGE receptor smooth muscle atherosclerosis; chemotaxis AGE
```

receptor smooth muscle atherosclerosis
(lesion; receptor for advanced glycation end products mediates chemotaxis of rabbit smooth muscle cells in relation to receptor-mediated endocytosis, transforming growth factor-.beta. secretion, foam cells, and atherosclerotic lesions)
(receptor for advanced glycation end products mediates chemotaxis of rabbit smooth muscle cells in relation to receptor-mediated endocytosis, transforming growth factor-.beta. secretion, foam cells, and atherosclerotic lesions)
(receptor for advanced glycation end products mediates chemotaxis of rabbit smooth muscle cells in relation to receptor-mediated endocytosis, transforming growth factor-.beta. secretion, foam cells, and atherosclerotic lesions)
(receptors; receptor for advanced glycation end products mediates chemotaxis of rabbit smooth muscle cells in relation to receptor-mediated endocytosis, transforming growth factor-.beta. secretion, foam cells, and atherosclerotic lesions)
(receptors; receptor for advanced glycation end products mediates chemotaxis of rabbit smooth muscle cells in relation to receptor-mediated endocytosis, transforming growth factor-.beta. secretion, foam cells, and atherosclerotic lesions)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

```
=> s l2 and (benzoic(l)acid or phenoxy(l)isobutyric(l)acid)
         42974 BENZOIC
       3008179 ACID
         39392 BENZOIC(L)ACID
         18168 PHENOXY
          5445 ISOBUTYRIC
       3008179 ACID
            24 PHENOXY(L)ISOBUTYRIC(L)ACID
L4            1 L2 AND (BENZOIC(L)ACID OR PHENOXY(L)ISOBUTYRIC(L)ACID)

=> d scan

L4    1 ANSWERS   CAPLUS  COPYRIGHT 2001 ACS
CC   1-12 (Pharmacology)
TI   Novel Inhibitors of Advanced Glycation
     Endproducts (Part II)
ST   advanced glycation endproduct inhibitor
        (AGE-protein; inhibitors of advanced glycation
        endproducts)
        (inhibitors of advanced glycation
        endproducts)
        (inhibitors of advanced glycation
        endproducts)
        (inhibitors of advanced glycation endproducts)

ALL ANSWERS HAVE BEEN SCANNED


=> s l2 and benzoic(l)acid
         42974 BENZOIC
       3008179 ACID
         39392 BENZOIC(L)ACID
L5            1 L2 AND BENZOIC(L)ACID
```

V. Balasubramanian

=> s l2 and phenoxy
18168 PHENOXY
L6 1 L2 AND PHENOXY

=> d l5 bib abs hitstr

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2001 ACS
AN 2000:835182 CAPLUS
DN 134:247197
TI Novel Inhibitors of **Advanced Glycation Endproducts** (Part II)
AU Rahbar, Samuel; Yerneni, Kiran Kumar; Scott, Stephen; Gonzales, Noe; Lalezari, Iraj
CS Department of Diabetes, Endocrinology, and Metabolism, Gonda (Goldschmied) Diabetes and Genetic Research Center, City of Hope National Medical Center, Duarte, CA, 91010, USA
SO Mol. Cell Biol. Res. Commun. (2000), 3(6), 360-366
CODEN: MCBCFS; ISSN: 1522-4724
PB Academic Press
DT Journal
LA English
AB Enhanced formation and accumulation of **advanced glycation endproducts** (AGEs), have been implicated as a major pathogenesis process leading to diabetic complications, normal aging, atherosclerosis, and Alzheimer's Disease. Several potential drug candidates as AGE inhibitors have been reported recently. The aim of this study was to develop classes of novel inhibitors of **glycation**, AGE formation, and AGE-crosslinking and to investigate their effects through in vitro chem. and immunochem. assays. A total of 92 compds. were designed and synthesized. The first 63 compds. were reported before. Nearly half of the 29 novel inhibitors reported here are **benzoic acid** derivs. and related mols., and found to be potent inhibitors of multistage **glycation**, AGE formation, and AGE-protein crosslinking. All 29 compds. show some degrees of inhibitory activities as detected by the four assay methods, 9 compds. demonstrated high percent inhibition (PI) in all tests, 30 to 40 times stronger than aminoguanidine. (c) 2000 Academic Press.
RE.CNT 50
RE
(1) Al-Abed, Y; J Biol Chem 1996, V271, P2892 CAPLUS
(3) Anon; US 5514676 CAPLUS
(5) Baynes, J; Diabetes 1999, V48, P1 CAPLUS
(8) Bucala, R; Adv Pharmacol 1992, V23, P1 CAPLUS
(9) Bucala, R; Exp Physiol 1997, V82, P327 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l6 bib abs

L6 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2001 ACS
AN 1999:558280 CAPLUS
DN 131:317717
TI Novel Inhibitors of **Advanced Glycation Endproducts**
AU Rahbar, Samuel; Kumar Yernini, Kiran; Scott, Stephen; Gonzales, Noe; Lalezari, Iraj
CS Department of Diabetes, Endocrinology & Metabolism, City of Hope National Medical Center, Duarte, CA, 91010-0269, USA

V. Balasubramanian

SO Biochem. Biophys. Res. Commun. (1999), 262(3), 651-656
CODEN: BBRCA9; ISSN: 0006-291X
PB Academic Press
DT Journal
LA English
AB Enhanced formation and accumulation of **advanced glycation endproducts** (AGE's) have been proposed to play a major role in the pathogenesis of diabetic complications, aging, atherosclerosis, and Alzheimer disease leading to progressive and irreversible intermol. protein crosslinkings. This process is accelerated in diabetes and has been postulated to contribute to the development of a range of diabetic complications including nephropathy, retinopathy and neuropathy. Several potential drug candidates as AGE inhibitors have been reported recently. Aminoguanidine is the first drug extensively studied both in vitro and in vivo. The authors have developed a new class of compds. as potent inhibitors of **glycation** and AGE formation. The novel inhibitors reported here are aryl (and heterocyclic) ureido, and aryl (and heterocyclic) carboxamido **phenoxy** isobutyric acids and related mols., which were found by in vitro assay methods to be potent inhibitors of multiple stage of **glycation** and AGE formation.

RE.CNT 48
RE
(1) Al-Abed, Y; J Biol Chem 1996, V271, P2892 CAPLUS
(4) Baynes, J; Diabetes 1999, V48, P1 CAPLUS
(5) Beisswenger, P; Diabetes 1999, V48, P198 CAPLUS
(7) Booth, A; J Biol Chem 1997, V272, P5430 CAPLUS
(8) Brownlee, M; Science 1986, V232, P1629 CAPLUS
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	30.26	30.41

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.18	-1.18

STN INTERNATIONAL LOGOFF AT 14:25:33 ON 23 SEP 2001